PL397320A1 - Zastosowanie[1-(4-chlorofenylo)4-(4-morfolinylo)-2,5-dihydro-1H-imidazol-2-onu] do leczenia stanów lękowych u psów - Google Patents

Zastosowanie[1-(4-chlorofenylo)4-(4-morfolinylo)-2,5-dihydro-1H-imidazol-2-onu] do leczenia stanów lękowych u psów

Info

Publication number: PL397320A1
Authority: PL; Poland
Prior art keywords: imidazol; morpholinyl; chlorophenyl; dogs; dihydro
Prior art date: 2002-10-10

Application number

PL397320A

Other languages

English (en)

Other versions

PL238776B1 (pl

Inventor

Chris Rundfeldt

Rita Dost

Wolfgang Loscher

Andrea Tipold

Klaus Unverferth

Hans-Joachim Lankau

Original Assignee

Boehringer Ingelheim Vetmedica Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-10

Filing date

2003-10-09

Publication date

2012-02-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32094042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL397320(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-09 Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh

2012-02-13 Publication of PL397320A1 publication Critical patent/PL397320A1/pl

2021-10-04 Publication of PL238776B1 publication Critical patent/PL238776B1/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL397320A 2002-10-10 2003-10-09 Związek [1-(4-chlorofenylo)4-(4-morfolinylo)-2,5-dihydro-1Himidazol- 2-on] do zastosowania w leczeniu stanów lękowych u psów PL238776B1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41759002P	2002-10-10	2002-10-10
US60/417,590		2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en)	2002-10-10	2003-10-09	Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (2)

Publication Number	Publication Date
PL397320A1 true PL397320A1 (pl)	2012-02-13
PL238776B1 PL238776B1 (pl)	2021-10-04

Family

ID=32094042

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL397320A PL238776B1 (pl)	2002-10-10	2003-10-09	Związek [1-(4-chlorofenylo)4-(4-morfolinylo)-2,5-dihydro-1Himidazol- 2-on] do zastosowania w leczeniu stanów lękowych u psów
PL374603A PL214702B1 (pl)	2002-10-10	2003-10-09	Zastosowanie 1-(4-chlorofenylo) 4-(4-morfolinylo)-2,5-dihydro-1H-imidazol-2-onu jako zwiazku aktywnego do wytwarzania leku do leczenia epilepsji u psów

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL374603A PL214702B1 (pl)	2002-10-10	2003-10-09	Zastosowanie 1-(4-chlorofenylo) 4-(4-morfolinylo)-2,5-dihydro-1H-imidazol-2-onu jako zwiazku aktywnego do wytwarzania leku do leczenia epilepsji u psów

Country Status (27)

Country	Link
US (5)	US20050070537A1 (pl)
EP (3)	EP2036563A1 (pl)
JP (4)	JP4694202B2 (pl)
KR (2)	KR101110587B1 (pl)
CN (2)	CN1726040B (pl)
AR (1)	AR041573A1 (pl)
AT (1)	ATE418337T1 (pl)
AU (2)	AU2003273978B2 (pl)
BE (1)	BE2013C046I2 (pl)
BR (1)	BR0315225A (pl)
CA (2)	CA2501772C (pl)
CY (3)	CY1109961T1 (pl)
DE (1)	DE60325496D1 (pl)
DK (2)	DK1553952T3 (pl)
ES (2)	ES2908453T3 (pl)
FR (2)	FR13C0044I2 (pl)
HR (3)	HRP20090667B1 (pl)
HU (2)	HUS1300035I1 (pl)
LU (1)	LU92238I2 (pl)
MX (1)	MXPA05003663A (pl)
NZ (1)	NZ539864A (pl)
PL (2)	PL238776B1 (pl)
PT (2)	PT1553952E (pl)
SI (2)	SI1553952T1 (pl)
TW (2)	TWI324067B (pl)
WO (1)	WO2004032938A1 (pl)
ZA (1)	ZA200502245B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
JP2009513539A (ja) *	2003-07-11	2009-04-02	ベーリンガー・インゲルハイム・フエトメデイカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング	ベンゾジアゼピンレセプターのアルファ３サブユニットに対する選択性を有する化合物を用いて中枢神経系障害を治療または予防する方法
AR089646A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
JP6193613B2 (ja) *	2013-05-10	2017-09-06	学校法人麻布獣医学園	てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
WO2015182724A1 (ja)	2014-05-28	2015-12-03	トーアエイヨー株式会社	置換トロパン誘導体
WO2016044370A1 (en)	2014-09-16	2016-03-24	India Globalization Capital, Inc.	Cannabinoid composition and method for treating pain
WO2016118391A1 (en)	2015-01-25	2016-07-28	India Globalization Capital, Inc.	Composition and method for treating seizure disorders
US10596159B2 (en)	2015-08-12	2020-03-24	India Globalization Capital, Inc.	Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en)	2016-06-15	2017-12-21	India Globalization Capital, Inc.	Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4044021A (en)	1971-10-21	1977-08-23	American Cyanamid Company	Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en)	1975-02-07	1976-01-13	Morton-Norwich Products, Inc.	1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de)	1995-09-05	1997-03-06	Dresden Arzneimittel	Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en)	1995-09-05	1999-02-09	Arzneitmittelwerk Dresden G.M.B.H.	Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) *	1997-05-23	1998-11-26	Dresden Arzneimittel	Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
EP0991614A1 (en) *	1997-06-26	2000-04-12	Board of Regents, The University of Texas System	Synthesis of dihydrohonokiol compositions
JP4669095B2 (ja)	1999-07-19	2011-04-13	太陽化学株式会社	ペットの問題行動抑制組成物
SI1870100T1 (sl)	2002-03-07	2012-05-31	Boehringer Ingelheim Int	Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de)	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AR089646A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals

2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW092127976A patent/TWI324067B/zh not_active IP Right Cessation
- 2003-10-08 TW TW098142077A patent/TWI424849B/zh not_active IP Right Cessation
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/hr not_active IP Right Cessation
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/zh not_active Expired - Lifetime
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/en not_active Ceased
- 2003-10-09 AR ARP030103685A patent/AR041573A1/es unknown
- 2003-10-09 EP EP08167818A patent/EP2036563A1/en not_active Ceased
- 2003-10-09 AT AT03757945T patent/ATE418337T1/de active
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/ko not_active Expired - Lifetime
- 2003-10-09 DK DK03757945T patent/DK1553952T3/da active
- 2003-10-09 PL PL397320A patent/PL238776B1/pl unknown
- 2003-10-09 SI SI200331504T patent/SI1553952T1/sl unknown
- 2003-10-09 EP EP03757945A patent/EP1553952B1/en not_active Expired - Lifetime
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/es active IP Right Grant
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/en not_active Expired - Lifetime
- 2003-10-09 PT PT03757945T patent/PT1553952E/pt unknown
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/ko not_active Ceased
- 2003-10-09 PL PL374603A patent/PL214702B1/pl unknown
- 2003-10-09 DE DE60325496T patent/DE60325496D1/de not_active Expired - Lifetime
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/ja not_active Expired - Lifetime
- 2003-10-09 HR HRP20050322AA patent/HRP20050322B1/hr not_active IP Right Cessation
- 2003-10-09 ES ES14191084T patent/ES2908453T3/es not_active Expired - Lifetime
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/zh active Pending
- 2003-10-09 SI SI200332622T patent/SI2845594T1/sl unknown
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/pt not_active Application Discontinuation
- 2003-10-09 CA CA2501772A patent/CA2501772C/en not_active Expired - Lifetime
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/da active
- 2003-10-09 CA CA2727722A patent/CA2727722C/en not_active Expired - Lifetime
- 2003-10-09 ES ES03757945T patent/ES2316808T3/es not_active Expired - Lifetime
- 2003-10-09 PT PT141910844T patent/PT2845594T/pt unknown
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
- 2003-10-09 HR HRP20200207AA patent/HRP20200207A2/hr not_active Application Discontinuation
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en not_active Expired - Lifetime
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/el unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/ja not_active Withdrawn
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
2013
- 2013-07-03 LU LU92238C patent/LU92238I2/fr unknown
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I2/el unknown
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/hu unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/fr active Active
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/ja not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Fee Related
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/ja not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/el unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/fr active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/hu unknown

Also Published As

Publication number	Publication date
EP2036563A1 (en)	2009-03-18
FR22C1033I1 (fr)	2022-09-09
WO2004032938A1 (en)	2004-04-22
LU92238I9 (pl)	2019-01-09
PT1553952E (pt)	2009-02-10
KR101110587B1 (ko)	2012-02-15
MXPA05003663A (es)	2005-06-08
KR20110063843A (ko)	2011-06-14
JP2011068685A (ja)	2011-04-07
FR13C0044I1 (pl)	2013-08-30
AU2009225322A1 (en)	2009-11-05
US20080027057A1 (en)	2008-01-31
US20130065898A1 (en)	2013-03-14
US8962617B2 (en)	2015-02-24
US9469611B2 (en)	2016-10-18
DE60325496D1 (de)	2009-02-05
FR13C0044I2 (fr)	2014-03-07
EP2845594B1 (en)	2022-02-23
NZ539864A (en)	2007-11-30
US20150072983A1 (en)	2015-03-12
US20050070537A1 (en)	2005-03-31
CY1125103T1 (el)	2023-01-05
AU2003273978B2 (en)	2009-07-23
JP2016104817A (ja)	2016-06-09
DK2845594T3 (da)	2022-03-07
TW200503726A (en)	2005-02-01
BE2013C046I2 (pl)	2022-08-09
CA2501772A1 (en)	2004-04-22
PL238776B1 (pl)	2021-10-04
KR20050056237A (ko)	2005-06-14
US20160367562A1 (en)	2016-12-22
LU92238I2 (fr)	2013-09-03
CA2501772C (en)	2011-08-23
BR0315225A (pt)	2005-08-23
HRP20090667A2 (hr)	2010-07-31
EP1553952B1 (en)	2008-12-24
CN1726040A (zh)	2006-01-25
ES2316808T3 (es)	2009-04-16
DK1553952T3 (da)	2009-04-20
JP6249812B2 (ja)	2017-12-20
HRP20090667B1 (hr)	2021-06-11
EP2845594A1 (en)	2015-03-11
SI2845594T1 (sl)	2022-04-29
PL374603A1 (pl)	2005-10-31
AU2003273978A1 (en)	2004-05-04
CA2727722C (en)	2013-05-28
HUS2200036I1 (hu)	2022-08-28
HK1085920A1 (zh)	2006-09-08
JP2006503873A (ja)	2006-02-02
US8859540B2 (en)	2014-10-14
PL214702B1 (pl)	2013-09-30
PT2845594T (pt)	2022-03-09
CA2727722A1 (en)	2004-04-22
ATE418337T1 (de)	2009-01-15
CY2013031I1 (el)	2015-11-04
CY2013031I2 (el)	2015-11-04
JP2014080449A (ja)	2014-05-08
EP1553952A1 (en)	2005-07-20
AR041573A1 (es)	2005-05-18
TWI424849B (zh)	2014-02-01
HRP20050322A2 (en)	2006-05-31
HUS1300035I1 (hu)	2017-10-30
ES2908453T3 (es)	2022-04-29
HRP20050322B1 (hr)	2013-12-06
CN101890019A (zh)	2010-11-24
HRP20200207A2 (hr)	2020-07-24
JP4694202B2 (ja)	2011-06-08
SI1553952T1 (sl)	2009-04-30
CY1109961T1 (el)	2014-09-10
TW201010706A (en)	2010-03-16
ZA200502245B (en)	2005-11-30
CN1726040B (zh)	2010-05-12
TWI324067B (en)	2010-05-01

Publication	Publication Date	Title
ZA200700481B (en)	2008-10-29	N-(1-(1-beznyl-4-pheynl-1H-imidazol-2-yl)-2,2-dymenthylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
PL376373A1 (pl)	2005-12-27	Wybrani antagoniści CGRP, sposoby ich wytwarzaniai ich zastosowanie jako leki
IL168056A0 (en)	2009-02-11	Selected cgrp antagonists, method for production and use thereof as medicament
AP2006003621A0 (en)	2006-06-30	Methods for treatment modification and management of pains using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoin-doleline
ATE430754T1 (de)	2009-05-15	Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
EP1651251A4 (en)	2008-06-18	METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
IS2980B (is)	2017-09-15	Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl
AP2004003161A0 (en)	2004-12-31	Substituted benzazoles and use thereof as raf kinase inhibitors.
EP1567161A4 (en)	2008-09-03	PHARMACEUTICAL COMPOSITION OF 1- (3,4-DIMETHOXYPHENYL) -4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND ITS USE
CY1125103T1 (el)	2023-01-05	Χρηση διυδροïμιδαζολονων για την αγωγη σκυλων
DK1185272T3 (da)	2004-08-09	Hidtil ukendt anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazin og dets fysiologisk acceptable salte til behandling af bipolære lidelser og mani
AU2003262033A8 (en)	2004-04-30	Method for managing use of storage region by application
EP1567198A4 (en)	2006-05-31	MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP1465968A4 (en)	2005-12-14	METHODS OF TREATING DISTILLATE DEODORIZER
EP1507528A4 (en)	2009-12-30	METHODS OF USING JNK INHIBITORS FOR TREATMENT OR PREVENTION OF DISEASE ASSOCIATED EMACIATION
AU2003255612A8 (en)	2003-12-19	Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
SI1727801T1 (sl)	2009-06-30	Piperazini, koristni za zdravljenje bolečine
FI20031628A0 (fi)	2003-11-10	Tietokoneryväs, tietokoneyksikkö ja menetelmä muistisaannin ohjaukseen tietokoneyksiköiden välillä
AU2003222022A1 (en)	2003-10-08	Methods for treating deodorizer distillate
IL157588A0 (en)	2004-03-28	Carbamate compounds for use in preventing or treating psychotic disorders
EP1680132A4 (en)	2009-01-14	METHOD FOR THE USE OF AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT, MODIFICATION AND SUPPLY OF FIBROMYALGIA
PL377857A1 (pl)	2006-02-20	Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków
ITMI20030287A1 (it)	2004-08-19	Indazolammidi dotate di attivita' analgesica metodo, per
PL376756A1 (pl)	2006-01-09	Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
AU2003297281A8 (en)	2004-06-15	Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors